Rana R. McKay, MD, Instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

In this analysis, statin users demonstrated an overall survival of 25.6 months compared with 18.9 months for non-users. This improvement was seen among patients receiving VEGF targeted therapy or mTOR targeted therapy. However, McKay says, no benefit was seen among patients receiving interferon or cytokine-based therapies.

Because of this, McKay says, statin use may be synergistic with VEGF or mTOR targeted therapies.

View more from the 2015 GU Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Genitourinary Cancers Symposium (ASCO GU)

Rana R. McKay, MD, discusses a study looking at statins and survival outcomes in patients with metastatic renal cell carcinoma.

Dr. McKay on Statin Use in Patients With mRCC